ACHN Achillion Pharmaceuticals, Inc.

+0  (1%)
Previous Close 3.99
Open 3.97
Price To book 1.37
Market Cap 548.25M
Shares 136,721,000
Volume 1,057,939
Short Ratio 6.78
Av. Daily Volume 1,415,500

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 screening recently updated as of February 23, 2017. Update due 1H 2017.
Paroxysmal nocturnal hemoglobinuria (PNH)
Phase 2b trial initiation announced November 30, 2016.
JNJ-4178 - OMEGA-1
Hepatitis C (HCV)

Latest News

  1. 4:06 pm Achillion Pharma announces that the U.S. Patent and Trademark Office has issued the first U.S. Patent to Achillion resulting from its complement factor D research program
  2. USPTO Grants Composition of Matter Patent to Achillion for Small Molecule Complement Alternative Pathway Factor D Inhibitors
  3. Achillion Pharmaceuticals, Inc. :ACHN-US: Earnings Analysis: Q4, 2016 By the Numbers : March 7, 2017
  4. These 5 Stocks Under $10 Could Explode Up Soon
  6. Achillion Pharmaceuticals to Support a Natural History Study of C3 Glomerulopathy, a Rare Renal Disorder, Conducted by Experts at Imperial College London
  7. Achillion (ACHN) Reports Narrower-Than-Expected Q4 Loss
  8. Biotech Movers: Cempra Flys High On Phase Three Results
  9. Achillion Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ACHN-US : February 24, 2017
  10. Achillion reports 4Q loss
  11. Achillion reports 4Q loss
  12. ACHILLION PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
  13. ACHILLION PHARMACEUTICALS INC Files SEC form 10-K, Annual Report
  14. Achillion Reports 2016 Fourth Quarter and Year-End Financial Results
  15. Biotech's Rally Continues to Build in 2017: Today's Reports on Achillion Pharmaceuticals and Pulmatrix
  16. Achillion to Present at the Leerink Partners 6th Annual Global Healthcare Conference
  17. Achillion Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ACHN-US : February 3, 2017
  18. Premarket Biotech Movers: Cytokinetics, Achillion, Qiagen
  19. Coverage initiated on Achillion Pharma by Ladenburg Thalmann
  20. Blog Coverage FDA Approved Orphan Drug Designation for TG Therapeutics' Combination of TG-1101 and TG-1202